Press Releases Imugene Limited

Equities

IMU

AU000000IMU9

Market Closed - Australian S.E. Other stock markets 07:10:13 28/06/2024 BST			5-day change	1st Jan Change
0.057 ^AUD	+5.56%		-3.39%	-48.18%

06-24	Imugene Doses First Patient of Bile Tract Cancer in Phase One Clinical Trial; Shares Decline 6%	MT
04-16	Imugene Signs Deal to Sell Manufacturing Facility For $6 Million	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Imugene partners with Kincell Bio; selling cell therapy manufacturing facility for $6 million	04-16	AQ
Bile Tract Cancer expansion study opens following clearance of Imugene’s MAST trial high dose cohort	04-15	AQ
Imugene opens enrolment for Bile Tract Cancer expansion study	04-15	AQ
Imugene's oncolytic virotherapy VAXINIA and B cell immunotherapy HER-Vaxx featured at the AACR Annual Meeting 2024	04-09	AQ
Imugene progresses onCARlytics solid tumour trial to combination arm	03-11	AQ
Phase 1 onCARlytics solid tumour trial advances to combination arm treatment	03-11	AQ
Imugene Highlights Recent Achievements and Looks Ahead to Key Upcoming Immuno-oncology Catalysts	02-22	AQ
Imugene doses first patient in intravenous monotherapy arm of Phase 1 clinical trial	02-15	AQ
MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs	01-23	AQ
Imugene Limited - VAXINIA MAST oncolytic virus Phase 1 trial doses first patients in higher dose cohorts	01-19	AQ
Imugene to commence new phase 2 PD1-Vaxx bowel cancer trial	12-06	AQ
Imugene thrilled as VAXINIA granted FDA Fast Track designation	11-28	AQ
Imugene says Azer-cel could be best-in-class Allogeneic CAR T	11-13	AQ
Imugene sees positive early signals in Phase 1 VAXINIA study	11-06	AQ
Imugene thrilled as first patient dosed in Phase 1 OASIS trial	26/10/23	AQ
Imugene welcomes positive FDA feedback on new manufacturing process for azer-cel	11/09/23	AQ
Imugene talks VAXINIA MAST trial and corporate ambition	04/09/23	AQ
Imugene doses first patient in PD1-Vaxx combination trial	01/06/23	AQ
Imugene secures IND approval for first-in-class onCARlytics trial	19/05/23	AQ
Imugene begins dosing in cohort three of VAXINIA monotherapy dose escalation trial	05/04/23	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Imugene Limited

Equities

IMU

AU000000IMU9

Press Releases

Filters